
|Videos|January 31, 2021
Glaukos COO shares product updates, 2021 pipeline
Author(s)David Hutton, Alex Delaney-Gesing
Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
2
Detecting peripheral retinal lesions in children with myopia
3
FDA grants priority review to Satralizumab sBLA for thyroid eye disease
4
4DMT completes enrollment in 4FRONT-2, global phase 3 trial of 4D-150 in wet AMD
5

























